FDA Approves ZITUVIMET XR — Zydus Pharmaceuticals USA Inc.
On July 18, Zydus Pharmaceuticals USA Inc. received FDA approval for the extended-release formulation of sitagliptin and metformin hydrochloride tablets (Brand name ZITUVIMET XR). The approval is anticipated to bolster branded competition and expand oral management options for type 2 diabetes drivers.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed